Segment Information (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

The following tables set forth our segment information for the three and six months ended June 30, 2024 and 2023, respectively (in thousands):

	Three Months Ended June 30, 2024
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	35,284		$	7,906		$	—		$	43,190
Operating expenses		58,361			26,133			6,014			90,508
Adjusted EBITDA(1)		(11,289	)		(7,033	)		(3,124	)		(21,446	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(23,077	)	$	(18,228	)	$	(4,943	)	$	(46,248	)
Net loss attributable to noncontrolling interest		—			—			26			26
Net loss attributable to Adaptive Biotechnologies Corporation		(23,077	)		(18,228	)		(4,917	)		(46,222	)
Interest and other income, net		—			—			(3,766	)		(3,766	)
Interest expense(2)		—			—			2,696			2,696
Depreciation and amortization expense		2,604			1,967			432			5,003
Impairment of long-lived assets(3)		2,819			4,386			—			7,205
Restructuring expense(3)		561			119			—			680
Share-based compensation expense(4)		5,804			4,723			2,431			12,958
Adjusted EBITDA(1)	$	(11,289	)	$	(7,033	)	$	(3,124	)	$	(21,446	)

	Three Months Ended June 30, 2023
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	25,882		$	23,044		$	—		$	48,926
Operating expenses		58,944			30,681			7,119			96,744
Adjusted EBITDA(1)		(23,079	)		1,264			(3,004	)		(24,819	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(33,063	)	$	(7,636	)	$	(7,112	)	$	(47,811	)
Net loss attributable to noncontrolling interest		—			—			1			1
Net loss attributable to Adaptive Biotechnologies Corporation		(33,063	)		(7,636	)		(7,111	)		(47,810	)
Interest and other income, net		—			—			(3,612	)		(3,612	)
Interest expense(2)		—			—			3,605			3,605
Depreciation and amortization expense		2,267			2,608			778			5,653
Share-based compensation expense(4)		7,717			6,292			3,336			17,345
Adjusted EBITDA(1)	$	(23,079	)	$	1,264		$	(3,004	)	$	(24,819	)

	Six Months Ended June 30, 2024
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	67,910		$	17,153		$	—		$	85,063
Operating expenses		118,247			49,974			12,922			181,143
Adjusted EBITDA(1)		(28,548	)		(13,960	)		(7,118	)		(49,626	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(50,337	)	$	(32,821	)	$	(10,623	)	$	(93,781	)
Net loss attributable to noncontrolling interest		—			—			52			52
Net loss attributable to Adaptive Biotechnologies Corporation		(50,337	)		(32,821	)		(10,571	)		(93,729	)
Interest and other income, net		—			—			(7,988	)		(7,988	)
Interest expense(2)		—			—			5,689			5,689
Depreciation and amortization expense		5,305			4,049			863			10,217
Impairment of long-lived assets(3)		2,819			4,386			—			7,205
Restructuring expense(3)		1,028			696			—			1,724
Share-based compensation expense(4)		12,637			9,730			4,889			27,256
Adjusted EBITDA(1)	$	(28,548	)	$	(13,960	)	$	(7,118	)	$	(49,626	)

	Six Months Ended June 30, 2023
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	47,309		$	39,264		$	—		$	86,573
Operating expenses		114,969			62,353			14,262			191,584
Adjusted EBITDA(1)		(49,465	)		(6,163	)		(6,289	)		(61,917	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(67,660	)	$	(23,088	)	$	(14,763	)	$	(105,511	)
Net loss attributable to noncontrolling interest		—			—			2			2
Net loss attributable to Adaptive Biotechnologies Corporation		(67,660	)		(23,088	)		(14,761	)		(105,509	)
Interest and other income, net		—			—			(6,636	)		(6,636	)
Interest expense(2)		—			—			7,136			7,136
Depreciation and amortization expense		4,323			5,361			1,392			11,076
Share-based compensation expense(4)		13,872			11,564			6,580			32,016
Adjusted EBITDA(1)	$	(49,465	)	$	(6,163	)	$	(6,289	)	$	(61,917	)

(1) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation for how it is calculated and used by management.

(2) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

(3) Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.

(4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.